<SEC-DOCUMENT>0001477932-17-003744.txt : 20170808
<SEC-HEADER>0001477932-17-003744.hdr.sgml : 20170808
<ACCEPTANCE-DATETIME>20170808170021
ACCESSION NUMBER:		0001477932-17-003744
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170808
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170808
DATE AS OF CHANGE:		20170808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		171015541

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ctxr_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title>ctxr_8k.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="center">
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><font size="3"><b>UNITED STATES</b></font></p>
<p style="MARGIN: 0px" align="center"><font size="3"><b>SECURITIES AND EXCHANGE COMMISSION</b></font></p>
<p style="MARGIN: 0px" align="center"><font size="3"><b>Washington, D.C. 20549</b></font></p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b><font size="6">FORM 8-K</font></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">CURRENT REPORT</p>
<p style="MARGIN: 0px" align="center">Pursuant to Section 13 or 15(d) of</p>
<p style="MARGIN: 0px" align="center">the Securities Exchange Act of 1934</p>
<p style="MARGIN: 0px" align="center">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Date of Report (Date of earliest event reported) <u><b>August 8, 2017</b></u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="55%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center"><b><font size="6">Citius Pharmaceuticals, Inc.</font></b></p></td></tr>
<tr>
<td>
<p style="MARGIN: 0px" align="center">(Exact name of registrant as specified in its charter)</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><u><b>Nevada</b></u></p>
<p style="MARGIN: 0px" align="center">(State or other jurisdiction of incorporation)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="3" cellpadding="0" width="85%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid" width="45%">
<p style="MARGIN: 0px" align="center"><b>333-206903 </b></p></td>
<td width="10%">
<p style="MARGIN: 0px" align="center"></td>
<td style="BORDER-BOTTOM: black 1px solid" width="45%">
<p style="MARGIN: 0px" align="center"><b>27-3425913 </b></p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="center">(Commission File Number)</p></td>
<td>
<p align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="center">(IRS Employer Identification No.)</p></td></tr>
<tr>
<td>
<p align="center">&nbsp;</p></td>
<td>
<p style="MARGIN: 0px" align="center"></td>
<td></td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center"><b>11 Commerce Drive, 1st Floor, Cranford, NJ </b></p></td>
<td>
<p style="MARGIN: 0px" align="center"></td>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center"><b>07016</b></p></td></tr>
<tr height="15">
<td>
<p style="MARGIN: 0px" align="center">(Address of principal executive offices)</p></td>
<td>
<p align="center">&nbsp;</p></td>
<td>
<p align="center">(Zip Code)</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center">Registrant's telephone number, including area code <u><b>(908) 967-6677</b> </u></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">&#168; </font>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">&#168; </font>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">&#168; </font>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">&#168; </font>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">Emerging growth company <font style="FONT-FAMILY: Wingdings">&#168;</font></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="FONT-FAMILY: Wingdings">&#168;<br></font>&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td>
<div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div>
<div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p>
<p style="MARGIN: 0px">
<table id="pagebreak136270b3-f602-4c3a-adcd-2e2a743a7df0" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="TEXT-ALIGN: center"></td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Item 8.01. Other Material Information.</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On August 8, 2017, Citius Pharmaceuticals, Inc. (the &#8220;Company&#8221;) announced that it closed its previously announced underwritten public offering. The Company sold an aggregate of 1,648,484 shares of its common stock (the &#8220;Common Stock&#8221;) and warrants to purchase an additional 1,648,484 shares of Common Stock (&#8220;Warrants&#8221;) at a combined offering price of $4.125. In addition, the underwriters partially exercised the over-allotment to purchase an additional 247,272 Warrants. The Warrants have a per share exercise price of $4.125, are exercisable immediately and will expire five years from the date of issuance. Gross proceeds to the Company from this offering are approximately $6,800,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Aegis Capital Corp. acted as the sole book-running manager for the offering and Dawson James Securities, Inc. acted as co-manager for the offering. </p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The Common Stock and Warrants were offered and sold to the public pursuant to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217956), which was declared effective on August 2, 2017, and a final prospectus filed on August 4, 2017.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">On August 8, 2017, the Company issued a press release entitled &#8220;Citius Pharmaceuticals, Inc. Announces Closing of Public Offering&#8221;. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px"><b>Item 9.01. Financial Statements and Exhibits</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px 0px 0px 45px">(d) <i>Exhibits.</i></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr height="15">
<td style="BORDER-BOTTOM: black 1px solid" valign="top" width="9%">
<p style="MARGIN: 0px"><b>Exhibit No.</b></p></td>
<td width="2%">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td style="BORDER-BOTTOM: black 1px solid" valign="top">
<p style="MARGIN: 0px"><b>Description of Exhibit</b></p></td></tr>
<tr>
<td>&nbsp;</td>
<td></td>
<td></td></tr>
<tr height="15" bgcolor="#cceeff">
<td valign="top">
<p style="MARGIN: 0px" align="left"><a href="ctxr_ex991.htm">99.1</a></p></td>
<td>
<p style="MARGIN: 0px">&nbsp;</p></td>
<td valign="top">
<p style="MARGIN: 0px"><a href="ctxr_ex991.htm">Press Release dated August 8, 2017</a></p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreak4c7116f7-bbdf-40ec-8e94-d015f917e088" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">3</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>SIGNATURE</b><b><u></u></b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px; TEXT-INDENT: 45px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td rowspan="0">&nbsp;</td>
<td colspan="2" rowspan="0"><b>CITIUS PHARMACEUTICALS, INC.</b></td>
<td rowspan="0"></td></tr>
<tr>
<td width="50%" rowspan="0">&nbsp;</td>
<td width="3%" rowspan="0">&nbsp;</td>
<td width="35%" rowspan="0">&nbsp;</td>
<td width="12%" rowspan="0">&nbsp;</td></tr>
<tr>
<td rowspan="0">Date: August 8, 2017</td>
<td rowspan="0">By:</td>
<td style="BORDER-BOTTOM: black 1px solid" rowspan="0"><i>/s/ Myron Holubiak</i></td>
<td rowspan="0"></td></tr>
<tr>
<td rowspan="0">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td rowspan="0">
<p style="MARGIN: 0px">&nbsp;</p></td>
<td rowspan="0">Myron Holubiak </td>
<td rowspan="0">&nbsp;</td></tr>
<tr>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>President and Chief Executive Officer </td>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid">
<p style="MARGIN: 0px" align="center">4</p></td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ctxr_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>ctxr_ex991.htm</title></head><body style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 99.1</b></p>
<p style="MARGIN: 0px" align="center"><b></b>&nbsp;</p>
<p style="MARGIN: 0px" align="center"><b>Citius Pharmaceuticals, Inc. Announces Closing of Public Offering</b></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b>CRANFORD, NJ, AUGUST 8, 2017 &#8211; CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR)</b>, a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today the closing of its previously announced underwritten public offering of 1,648,484 shares of its common stock and warrants to purchase up to an aggregate of 1,648,484 shares of its common stock at a combined offering price of $4.125. In addition, the underwriters partially exercised the over-allotment to purchase an additional 247,272 warrants. The warrants have a per share exercise price of $4.125, are exercisable immediately and will expire five years from the date of issuance. Gross proceeds to Citius from this offering are approximately $6,800,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by Citius.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">Aegis Capital Corp. acted as the sole book-running manager for the offering and Dawson James Securities, Inc. acted as co-manager for the offering.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">A registration statement on Form S-1 relating to these securities has been filed with the Securities and Exchange Commission and became effective on August 2, 2017. </p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">The offering will be made only by means of a prospectus. A copy of the prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor,&nbsp;New York, NY&nbsp;10019, telephone: 212-813-1010, e-mail:&nbsp;prospectus@aegiscap.com. Investors may also obtain these documents at no cost by visiting the SEC&#8217;s website at&nbsp;http://www.sec.gov. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the Securities and Exchange Commission for more complete information about the Company and the offering.</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><u>About Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) </u></b></p>
<p style="MARGIN: 0px" align="justify">Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches.&nbsp;www.citiuspharma.com</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px" align="justify">
<table id="pagebreak879697e1-0898-4b11-bd1e-918cc9b30223" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td class="hpbhr">&nbsp;</td></tr>
<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">1</td></tr>
<tr>
<td>
<div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr>
<tr>
<td>&nbsp;</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px" align="justify"><b><u>Safe Harbor Disclosure</u></b></p>
<p style="MARGIN: 0px" align="justify">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Citius, including but not limited to statements with respect to Citius&#8217;s planned use of proceeds. Citius may use words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;should,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes&#8221; and words and terms of similar substance to identify such forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are risks relating to, among other things, whether or not Citius will be able to raise capital, the final terms of the underwritten offering of common stock and warrants, market and other conditions, the satisfaction of customary closing conditions related to the underwritten offering of common stock and warrants, Citius&#8217;s business and financial condition, and the impact of general economic, industry or political conditions in&nbsp;the United States&nbsp;or internationally. For additional disclosure regarding these and other risks faced by Citius, see disclosures contained in Citius&#8217;s public filings with the SEC, including the &#8220;Risk Factors&#8221; in the company&#8217;s Annual Report on Form 10-K for the fiscal year ended&nbsp;September 30, 2016, and under the heading &#8220;Risk Factors&#8221; of the prospectus for this offering. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and Citius undertakes no obligation to update such statements as a result of new information.</p>
<p style="MARGIN: 0px" align="justify">&nbsp;</p>
<p style="MARGIN: 0px">Corporate Communications Contact: For Investors:</p>
<p style="MARGIN: 0px">Andrew Scott</p>
<p style="MARGIN: 0px">Vice President, Corporate Development</p>
<p style="MARGIN: 0px">(O) 908-967-6676</p>
<p style="MARGIN: 0px">ascott@citiuspharma.com</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">&nbsp;</p>
<p style="MARGIN: 0px">
<table id="pagebreakd74eb2c8-e4cc-404d-849a-f265c96922dc" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0">

<tr>
<td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center">2</td></tr></table></p>
<p style="MARGIN: 0px">&nbsp;</p></BODY></html></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
